Predictive Risk Score for Acute Kidney Injury in Hematopoietic Stem Cell Transplant

Data de publicação: 01/07/2023 Data Ahead of Print: 22/07/2023

Autores da FMUP

• Joaquim Adelino Correia Ferreira Leite Moreira

  Autor

Participantes de fora da FMUP

• Rodrigues, N
• Fragao Marques, M
• Costa, C
• Branco, C
• Marques, F
• Vasconcelos, P
• Martins, C
• Lopes, JA

Unidades de investigação

• Cirurgia e Fisiologia

• Laboratório Associado RISE- Rede de Investigação em Saúde

  

  Investigador

  Fernando Carlos De Landér Schmitt

• RISE-Health

  

  Investigador

  Fernando Carlos De Landér Schmitt

Abstract

Simple Summary The incidence and prevalence of hematologic malignancies are increasing throughout the world and hematopoietic stem cell transplant contributes to significantly better outcomes. Acute kidney injury is a frequent complication of hematopoietic stem cell transplants and has known implications for overall survival. We calculated the first simple, easily assessed, inexpensive predictive risk score that helps identify patients with hematologic malignancies undergoing a hematopoietic stem cell transplant at risk for AKI. Hematopoietic stem cell transplant (HSCT) is an important treatment option for hematologic malignancies. Acute kidney injury (AKI) is a common complication in HSCTs and is related to worse outcomes. We aimed to create a predictive risk score for AKI in HSCT considering variables available at the time of the transplant. We performed a retrospective cohort study. AKI was defined by the KDIGO classification using creatinine and urinary output criteria. We used survival analysis with competing events. Continuous variables were dichotomized according to the Liu index. A multivariable analysis was performed with a backward stepwise regression. Harrel's C-Statistic was used to evaluate the performance of the model. Points were attributed considering the nearest integer of two times each covariate's hazard ratio. The Liu index was used to establish the optimal cut-off. We included 422 patients undergoing autologous (61.1%) or allogeneic (38.9%) HSCTs for multiple myeloma (33.9%), lymphoma (27.3%), and leukemia (38.8%). AKI cumulative incidence was 59.1%. Variables eligible for the final score were: hematopoietic cell transplant comorbidity index & GE;2 (HR: 1.47, 95% CI: 1.08-2.006; p = 0.013), chronic kidney disease (HR: 2.10, 95% CI: 1.31-3.36; p = 0.002), lymphoma or leukemia (HR: 1.69, 95% CI: 1.26-2.25; p < 0.001) and platelet-to-lymphocyte ratio > 171.9 (HR: 1.43, 95% CI: 1.10-1.86; p = 0.008). This is the first predictive risk score for AKI in patients undergoing HSCTs and the first study where the platelet-to-lymphocyte ratio is independently associated with AKI.

Keywords

• stem cell transplant; risk factors; predictive risk score